TP53 and colorectal carcinoma: IACS-010759 treatment inhibited the viability to varying degrees in these glycolysis-competent CRC cell lines, with notable sensitivity in cells carrying wildtype p53 (RKO, HCT116, LIM1215) compared to mutant p53 counterparts (Colo205, Caco-2, LS411N, SW620), similar to NB-1 cells (Fig. 1A).